Predictive value of CRP vs LDL-C (i) Ridker PM, et al. N Engl J Med 2002;347:1557-1565. Quintile of CRP (mg/L) <0.0012.32.01.61.41.0 Adjusted RR* of a.

Slides:

Advertisements

Similar presentations

Nonsense Mutations in PCSK9 and Cardiovascular Risk Factors among 3363 Black Participants in the Study Jonathan C.Cohen, et al, N Engl J Med 2006;354:

Advertisements

Lipid Disorders and Management in Diabetes

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:

Cholesterol quintile (mg/dL)

Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.

Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?

LIPID LOWERING IN T2D (The Lower the Better?) CONS… TARGETING HARD CVD END POINTS Charles SAAB MD Consultant Endocrinologist DCRP Sacre-Coeur University.

Slide Source: Lipids Online Slide Library Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients.

(N=488) Simvastatin in Patients With Prior Cerebrovascular Disease: HPS *29% RRR, p=0.001 Heart Protection Study Collaborative Group. Lancet. 2004;363:

Glucose Levels and Risk of Dementia Presented by - Anas Kabaha, MD Sheba medical center Sheba medical center August 8,2013.

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

Women and Cholesterol What You Need to Know. Age: 45 Women and Cholesterol: What You Need to Know HDL: 60 mg/dL and above LDL: Below 100 mg/dL GoodBad.

Cost-Effectiveness of hsCRP Screening 1. Adjunct to Global Risk Assessment 2. Method to Monitor Statin Efficacy in Secondary Prevention 3. Method to Target.

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

Modern Management of Cholesterol in the High-Risk Patient.

«Blood stroke» Abdurashitov & Bezsonov. Stroke.What is? A stroke, or cerebrovascular accident (CVA), is the rapid loss of brain function(s) due to disturbance.

Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.

Zacho J, et al. N Engl J Med 2008;359: Risk of Ischemic Heart Disease as a Function of Plasma Levels of C-Reactive Protein (CRP) in the General.

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Albuminuria; a tool for measuring non-blood pressure.

Pai JK et al. N Engl J Med 2004; 351: Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP

1 INTIMA MEDIA THICKNESS AND ATHEROSCLEROSIS Michele CAZAUBON, MD, PhD American Hospital of Paris ( France)

The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.

To assess the prognostic value of variability in home-measured blood pressure (BP) and heart rate (HR) in a general population. Objective: Methods: BP.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyorala K for the 4S Group Reduced Coronary Events in Simvastatin-Treated.

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:

Slide Source: Lipids Online Slide Library LDL Cholesterol, mg/dL Years of Follow-up Ridker PM et al. N Engl J Med 2002;347:1557–1565.

BRIAN CLAYTON INTERNAL MEDICINE ADVISOR: ANNA MAE SMITH PRECEPTOR: DR. RAJESH PATEL Evidence Based Medicine Spring 2009.

Mechanism of Action of Aspirin Carlo Patrono, et al, N Engl J Med 2005;353:

Baseline Prevalence of Metabolic Syndrome and Individual Components Among 4258 Older Adults Dariush Mozaffarian, et al. Arch Intern Med. 2008;168:

Slide Source: Lipids Online Slide Library C-Reactive Protein, Metabolic Syndrome, and Risk for CV Events: Women’s Health Study 14,719.

Parish S, et al. Eur Heart J 2009 [Epub ahead of print]

Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Hypertension J Am Coll Cardiol. 2006;48(8):

Case 1: Elevated LDL-C in a Young Adult. Page 2 of 10 *DALY; disability-adjusted life years Routine checkup:  Age:33 years  Sex: male  Status: Except.

Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Genetic Inhibition of CETP, Ischemic Vascular Disease.

Date of download: 6/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Urinary Sodium and Potassium Excretion and Risk of.

Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Test in Context: High-Sensitivity C-Reactive Protein.

Predicted 5-year benefits of LDL cholesterol reductions with statin treatment at different levels of risk. (A) Major vascular events, and (B) vascular.

2013 ACC/AHA cholesterol treatment guidelines

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

AHA 2017 Residual Inflammatory Risk and Residual Cholesterol Risk:

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

HDL cholesterol and cardiovascular risk

Oxford Niacin Trial.

ACC 2018 Orlando, Florida Interleukin-1b Inhibition with Canakinumab and Cardiovascular Event Reduction Among Patients with Moderate Chronic Kidney Disease.

Adjusted relative mortality risk

A: Epidemiology update

Lipoprotein insulin resistance score and risk of incident diabetes during extended follow- up of 20 years: The Women's Health Study Paulo H.N. Harada,

Relative risk of hypertension by quintiles of lipids (mg/dL)

Description of studies for pooled analyses

2013 ACC/AHA cholesterol treatment guidelines

Baseline Characteristics of the Study Cohort*

Cystatin C levels and risk of death from all causes

Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%

Clinical Characteristics and Atheroma Burden of Subjects at Baseline Stratified According to Gender Nicholls SJ. et al. J Am Coll Cardiol 2007;49:

Characteristics of Study Subjects and Events, According to the Quintile of Exposure to Fine Particulate Matter (PM2.5)* - Part I Kristin A. Miller et al.

Baseline Characteristics, Blood Pressures, and Laboratory Values

Baseline Characteristics of the Subjects*

Women’s Health Study: Baseline Characteristics Part 1

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

End point Valsartan Valsartan+HCTZ p

ACC 2018 Orlando, Florida Interleukin-1b Inhibition with Canakinumab and Cardiovascular Event Reduction Among Patients with Moderate Chronic Kidney Disease.

Presentation transcript:

Predictive value of CRP vs LDL-C (i) Ridker PM, et al. N Engl J Med 2002;347: Quintile of CRP (mg/L) < Adjusted RR* of a first cardiovascular event p value>4.19>2.09 to 4.19 >1.08 to 2.09 >0.49 to 1.08 < 0.49 * relative risk adjusted for age, smoking status, the presence or absence of diabetes mellitus, blood pressure, use or nonuse of hormone replacement therapy, and treatment assignment

Predictive value of CRP vs LDL-C (ii) Quintile of LDL-C (mg/dL) < Adjusted RR* of a first cardiovascular event p value>153.9>132.2 to >115.4 to >97.6 to < 97.6 * relative risk adjusted for age, smoking status, the presence or absence of diabetes mellitus, blood pressure, use or nonuse of hormone replacement therapy, and treatment assignment Ridker PM, et al. N Engl J Med 2002;347:

High CRP/low LDL-C predicts high risk Age-adjusted event rates per 1000 person- years High CRP High LDL High CRP Low LDL Low CRP High LDL Low CRP Low LDL* * Low and high refer to levels below and above the median values of CRP (1.52 mg/L) and LDL-C (123.7 mg/dL) Ridker PM, et al. N Engl J Med 2002;347: